Bezin J, Gouverneur A, Penichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023; 46(2):384-390.
Brandfon S, Eylon A, Khanna D, Parmar MS. Advances in anti-obesity pharmacotherapy: Current treatments, emerging therapies, and challenges. Cureus. 2023;15(10):e46623. Published 2023 Oct 7. doi:10.7759/cureus.46623.
Caruso A, Gelsomino L, Panza S, et al. Leptin: A heavyweight player in obesity-related cancers. Biomolecules. 2023;13(7):1084.
Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. Obesity management in adults: A review. JAMA. 2023 Nov 28;330(20):2000-15. doi:10.1001/jama.2023.1989.
Ganipisetti VM, Bollimunta P. Obesity and set-point theory. [Updated 2023 Apr 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Accessed at https://www.ncbi.nlm.nih.gov/books/NBK592402/ on July 30, 2025.
Ibrahim SS, Ibrahim RS, Arabi B, et al. The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. Cancer Metastasis Rev. Published online May 27, 2024. doi:10.1007/s10555-024-10192-9.
Khalilov R, Abdullayeva S. Mechanisms of insulin action and insulin resistance. Advances in Biology & Earth Sciences. 2023;8(2).
Lin C, et al. Comparative risk of obesity-related cancer with glucagon-like protein-1 receptor agonists vs. bariatric surgery in patients with BMI >35. Journal of Clinical Oncology. 2024; 42(16):suppl. doi.org/10.1200/JCO.2024.42.16_suppl.10508.
López M, Nogueiras R. Ghrelin. Current Biology. 2023;33(21):R1133-1135. DOI: 10.1016/j.cub.2023.09.009
Sun Y, Liu Y, Dian Y, Zeng F, Deng G, Lei S. Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials. Int J Surg. 2024;110(8):4688-4694. Published 2024 Aug 1. doi:10.1097/JS9.0000000000001514.
US Preventive Services Task Force. About prevention taskforce. U.S. Protective Services Task Force. Accessed July 30, 2025. https://www.uspreventiveservicestaskforce.org/apps/about.jsp.